A Phase 2 interventional study of Alisertib and Paclitaxel in Ovarian Carcinoma, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-04.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.
Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 24th largest by enrollment of the 143 interventional ones that give a count, is one of 11 that started in 2010, is one of 83 in phase 2, and was the 85th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Women only
ARCAGY/ GINECO GROUP · Sites in France, Italy, Japan and 1 more country
Ages 18+ · Women only
The University of Hong Kong · Sites in Hong Kong
Ages 18+ · Women only
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–75 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 93 · Phase 3 28 · Phase 4 1
First in 1991; this study’s year is marked. 11 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 50 across the 143 interventional studies. Of the 107 that completed or were terminated, 41 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 155 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
11 studies in Ovarian Neoplasms by Takeda: none open now, 1 under way, none of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 11 studies in Ovarian Neoplasms by Takeda, this one is the only one that started in 2010, is one of 5 in phase 2, and was the 4th registered.
Takeda’s Ovarian Neoplasms studies by the year they started, since 2002.
4 of the studies testing paclitaxel in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
| NCT06492070Emory UniversityCryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | 2026-12-31 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing paclitaxel in Ovarian Neoplasms, from their registry updates:
Among Takeda’s 11 in Ovarian Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).
The drug tested in this study was called alisertib. Alisertib was tested to treat people who have ovarian and breast cancer. This study looked at safety, any anti-tumor effect, and it also determined a recommended dose of alisertib plus paclitaxel to take into further studies. Pharmacokinetic blood samples were studied to characterize any effects on the concentration of each of the drugs when administered together.
The study enrolled 191 patients. Participants with Breast Cancer and Ovarian Cancer received one of the following escalating doses of alisertib in combination with paclitaxel in the Phase 1 lead-in portion of the study:
Once the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) was determined, participants were randomized to receive the following treatments in the Phase 2 portion of the study:
This multi-center trial was conducted in the United States, Poland and France. The overall time to participate in this study was approximately 5 years. Participants made multiple visits to the clinic, and who did not experience disease progression (PD) were followed off-treatment once every 8 weeks until the occurrence of 110 progression-free survival (PFS) events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Specific Inclusion Criteria for participants with Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer:
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
Drug: Alisertib · Drug: Paclitaxel
Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
Drug: Alisertib · Drug: Paclitaxel
Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
Drug: Alisertib · Drug: Paclitaxel
Paclitaxel 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
Drug: Paclitaxel
Alisertib tablets
Also known as: MLN8237
Paclitaxel intravenous infusion
Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel
The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.
Time frame: Cycle 1 (Up to 28 days)
Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib
The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of cycle 1).
Time frame: Cycle 1 (Up to 28 days)
Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose to 30 days past last dose (Up to 36 Months)
Phase 1: Number of Participants With Clinically Significant Laboratory Values
Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
Time frame: First dose to 30 days past last dose (Up to 36 Months)
Phase 1: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
Time frame: First dose to 30 days past last dose (Up to 36 Months)
Phase 1: Number of Participants With Hypersensitivity and Neurotoxicity
Time frame: Baseline up to Month 36
Phase 2: Progression-Free Survival (PFS)
PFS is defined as the time from the date randomization for Phase 2 participants to the date of first documented progressive disease (PD) or death as assessed by the investigator using both RECIST 1.1 criteria and CA-125 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.
Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Phase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer
Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).
Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Cmax: Maximum Observed Concentration for Alisertib in Phase 1
Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Tmax: Time to First Occurrence of Cmax for Alisertib in Phase 1
Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
AUC(Tau): Area Under the Concentration-Time Curve During a Dosing Interval for Alisertib in Phase 1
Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Phase 1
Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Cmax: Maximum Observed Concentration for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
t½: Terminal Half-Life for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
CL: Total Clearance After Intravenous Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Vss: Volume of Distribution at Steady State for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Vz: Volume of Distribution During the Terminal Disposition Phase for Paclitaxel in Phase 1
Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Phase 2: Combined Best Overall Response Rate (ORR)
Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).
Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Phase 2: Duration of Response (DOR)
DOR was defined as the time from the date of first documentation of a response to the date of first documentation of PD or the last response assessment that is stable disease (SD) or better for a participant who started alternate therapy without progression. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. A responder that did not experience disease progression is censored at the last response assessment that is SD.
Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)
Phase 2: Time to Disease Progression (TTP)
TTP was defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.
Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)
Phase 2: Overall Survival (OS)
OS was defined as the time form the date of the randomization to the date of death.
Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)
Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose to 30 days past last dose (Up to 27 Months)
Phase 2: Number of Participants With Clinically Significant Laboratory Values
Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
Time frame: First dose to 30 days past last dose (Up to 27 Months)
Phase 2: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
Time frame: First dose to 30 days past last dose (Up to 27 Months)
Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes
Time frame: Up to 24 Months
Participants took part in the study at 33 investigative sites in France, Poland and the United States from 16 April 2010 to 19 July 2017. Data cutoff for the primary analysis was 12 August 2014.
| Milestone | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|---|---|
| Started | 38 | 11 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 38 | 11 | 0 | 0 |
| Withdrew: Progressive disease | 24 | 8 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 3 | 2 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 0 |
| Withdrew: Single-patient ind | 2 | 0 | 0 | 0 |
| Milestone | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|---|---|
| Started | 0 | 0 | 73 | 69 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 73 | 69 |
| Withdrew: Progressive disease | 0 | 0 | 44 | 46 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 12 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 9 | 8 |
| Withdrew: Unsatisfactory therapeutic response | 0 | 0 | 1 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 4 | 3 |
| Withdrew: Physician decision | 0 | 0 | 2 | 0 |
The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.
| mg | Alisertib + Paclitaxel (Phase 1) |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel | 40 |
The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of cycle 1).
| mg/m^2 | Alisertib + Paclitaxel |
|---|---|
| Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib | 60 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) |
|---|---|---|
| AEs | 38 | 11 |
| SAEs | 13 | 2 |
Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
| participants | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) |
|---|---|---|
| Neutrophil count decreased | 3 | 0 |
| White blood cell count decreased | 1 | 1 |
| Aspartate aminotransferase increased | 3 | 1 |
| Alanine aminotransferase increased | 2 | 0 |
| Ammonia increased | 1 | 0 |
| Transaminases increased | 1 | 0 |
| Blood alkaline phosphatase increased | 1 | 1 |
| High density lipoprotein decreased | 1 | 0 |
| Urine output decreased | 1 | 0 |
| Granulocyte count decreased | 0 | 1 |
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
| participants | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) |
|---|---|---|
| Pyrexia | 8 | 5 |
| Heart rate irregular | 1 | 0 |
| Blood pressure increased | 0 | 1 |
| Weight decreased | 3 | 0 |
| participants | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) |
|---|---|---|
| Hypersensitivity | 1 | 0 |
| Neurotoxicity | 0 | 0 |
PFS is defined as the time from the date randomization for Phase 2 participants to the date of first documented progressive disease (PD) or death as assessed by the investigator using both RECIST 1.1 criteria and CA-125 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.
| days | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Phase 2: Progression-Free Survival (PFS) | 204 (175 to 230) | 142 (117 to 148) |
Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).
| percentage of participants | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) |
|---|---|---|
| Phase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer | 47 (36 to 59) | 55 (32 to 76) |
| ng/mL | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle1 (Day1) | 428.7 ± 189.59 | 766.8 ± 312.10 | 900.00 ± 392.17 | 1365.3 ± 466.51 | 1398.7 ± 607.70 | 1960.0 ± 515.65 |
| Cycle1 (Day3) | 594.3 ± 228.46 | 1042.3 ± 280.95 | 871.3 ± 268.23 | 1708.5 ± 820.54 | 2493.4 ± 955.31 | 4456.7 ± 947.33 |
| hour | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 3.0 ± 189.59 | 3.1 ± 312.10 | 2.6 ± 392.17 | 2.5 ± 466.51 | 3.0 ± 607.70 | 2.0 ± 515.65 |
| Cycle 1, Day 3 | 2.2 ± 228.46 | 3.0 ± 280.95 | 3.5 ± 268.23 | 2.0 ± 820.54 | 2.0 ± 955.31 | 2.0 ± 947.33 |
| ng/mL*hour(hr) | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 2519.3 ± 937.52 | 5175.0 ± 1766.11 | 5610.0 ± 2105.42 | 8581.7 ± 3225.64 | 9594.0 ± 4600.42 | 14666.7 ± 3707.20 |
| Cycle 1, Day3 | 3966.7 ± 1112.11 | 7745.0 ± 2233.91 | 6155.0 ± 1737.69 | 12478.3 ± 6013.93 | 17557.3 ± 7856.30 | 35500.0 ± 12842.12 |
| ng/mL*hr | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 2519.3 ± 937.52 | 5175.0 ± 1766.11 | 5610.0 ± 2105.42 | 8581.7 ± 3225.64 | 9594.0 ± 4600.42 | 14666.7 ± 3707.20 |
| Cycle 1, Day 3 | 3966.7 ± 1112.11 | 7745.0 ± 2233.91 | 6155.0 ± 1737.69 | 12478.3 ± 6013.93 | 17557.3 ± 7856.30 | 35500.0 ± 12842.12 |
| ng/mL | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 3097.3 ± 1114.51 | 3120.0 ± 447.75 | 2117.5 ± 745.54 | 2448.0 ± 988.65 | 1917.3 ± 528.32 | 1338.7 ± 617.94 |
| Cycle 2, Day 1 | 2654.6 ± 696.45 | 3231.7 ± 615.64 | 1733.3 ± 541.97 | 2478.3 ± 878.39 | 1492.7 ± 558.14 | 1750.0 ± 183.85 |
| ng/mL*hr | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 4437.7 ± 1053.87 | 4825.0 ± 735.17 | 3355.0 ± 865.89 | 3366.0 ± 1139.25 | 2652.7 ± 651.32 | 2190.0 ± 387.43 |
| Cycle 2, Day 1 | 4061.7 ± 1298.86 | 5301.7 ± 1183.31 | 2660.0 ± 307.90 | 3056.0 ± 812.67 | 2231.5 ± 604.76 | 2460.0 ± 14.14 |
| ng/mL*hr | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 5317.8 ± 1052.40 | 5238.0 ± 812.26 | 3860.0 ± 824.20 | 3375.0 ± 1130.56 | 3175.5 ± 933.10 | 2535.0 ± 657.61 |
| Cycle 2, Day 1 | 4606.4 ± 1391.35 | 5584.0 ± 1367.51 | 3185.0 ± 176.78 | 3415.0 ± 1010.82 | 2680.0 ± 607.22 | — |
| hour | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 17.2 ± 4.20 | 17.5 ± 1.87 | 17.3 ± 4.16 | 13.9 ± 4.68 | 16.8 ± 6.83 | 18.4 ± 8.70 |
| Cycle 2, Day 1 | 17.0 ± 3.63 | 16.2 ± 5.05 | 17.3 ± 5.23 | 16.5 ± 4.32 | 13.3 ± 5.59 | 14.6 ± 2.19 |
| liter per hour | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 29.756 ± 6.8175 | 28.220 ± 5.1804 | 26.800 ± 7.5386 | 40.950 ± 17.5268 | 38.055 ± 13.7095 | 38.950 ± 11.2430 |
| Cycle 2, Day 1 | 35.827 ± 10.4005 | 28.240 ± 7.3748 | 33.900 ± 5.2326 | 34.250 ± 8.2614 | 42.440 ± 10.4296 | — |
| liter | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 313.444 ± 118.6593 | 310.800 ± 86.9235 | 330.000 ± 208.8851 | 357.000 ± 158.1834 | 433.909 ± 179.7757 | 460.500 ± 103.9447 |
| Cycle 2, Day 1 | 391.364 ± 64.3137 | 283.200 ± 121.1123 | 413.500 ± 242.5376 | 377.000 ± 118.9650 | 372.600 ± 180.7332 | — |
| liter | Alisertib 10 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 80 mg/m^2 | Alisertib 20 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 30 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 | Alisertib 50 mg BID + Paclitaxel 60 mg/m^2 |
|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 705.000 ± 179.0223 | 721.600 ± 203.8021 | 694.000 ± 352.1534 | 850.500 ± 291.0401 | 872.727 ± 328.6202 | 956.500 ± 188.7975 |
| Cycle 2, Day 1 | 829.364 ± 156.6060 | 663.200 ± 321.3070 | 865.500 ± 388.2016 | 777.250 ± 103.7027 | 733.000 ± 208.4898 | — |
Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).
| percentage of participants | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Phase 2: Combined Best Overall Response Rate (ORR) | 60 (51 to 68) | 52 (43 to 60) |
DOR was defined as the time from the date of first documentation of a response to the date of first documentation of PD or the last response assessment that is stable disease (SD) or better for a participant who started alternate therapy without progression. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. A responder that did not experience disease progression is censored at the last response assessment that is SD.
| days | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Phase 2: Duration of Response (DOR) | 201 (181 to 218) | 169 (120 to 231) |
TTP was defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.
| days | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Phase 2: Time to Disease Progression (TTP) | 204 (175 to 232) | 142 (117 to 161) |
OS was defined as the time form the date of the randomization to the date of death.
| days | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Phase 2: Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| AEs | 73 | 66 |
| SAEs | 30 | 19 |
Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
| participants | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Neutrophil count decreased | 14 | 4 |
| White blood cell count decreased | 6 | 1 |
| Lymphocyte count decreased | 1 | 1 |
| Aspartate aminotransferase increased | 1 | 3 |
| Alanine aminotransferase increased | 1 | 4 |
| Gamma-glutamyltransferase increased | 0 | 1 |
| Blood alkaline phosphatase increased | 2 | 2 |
| Haemoglobin decreased | 3 | 1 |
| Blood magnesium decreased | 0 | 3 |
| Blood creatinine increased | 1 | 2 |
| Platelet count decreased | 2 | 0 |
| International normalised ratio increased | 1 | 0 |
| Blood albumin decreased | 1 | 0 |
| Troponin T increased | 0 | 1 |
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
| participants | Alisertib 40 mg BID + Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|
| Pyrexia | 15 | 8 |
| Heart rate increased | 1 | 0 |
| Blood pressure increased | 1 | 0 |
| Weight decreased | 8 | 2 |
No measurements were reported for this outcome.
Collected over Phase 1: First dose to 30 days past last dose (Up to 36 Months); Phase 2: First dose to 30 days past last dose (Up to 27 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib (Phase 1 - Ovarian Cancer) | — | 13/38 (34.2%) | 38/38 (100%) |
| Alisertib (Phase 1 - Breast Cancer) | — | 2/11 (18.2%) | 11/11 (100%) |
| Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | — | 30/73 (41.1%) | 73/73 (100%) |
| Paclitaxel 80 mg/m^2 (Phase 2) | — | 19/69 (27.5%) | 64/69 (92.8%) |
| Event | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/38 | 0/11 | 9/73 | 0/69 |
| CellulitisInfections and infestations | 1/38 | 1/11 | 0/73 | 0/69 |
| SepsisInfections and infestations | 0/38 | 1/11 | 1/73 | 1/69 |
| PyrexiaGeneral disorders | 0/38 | 1/11 | 3/73 | 2/69 |
| FatigueGeneral disorders | 1/38 | 1/11 | 0/73 | 1/69 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/38 | 1/11 | 2/73 | 1/69 |
| HypotensionVascular disorders | 1/38 | 1/11 | 0/73 | 0/69 |
| NeutropeniaBlood and lymphatic system disorders | 0/38 | 0/11 | 6/73 | 0/69 |
| Intestinal obstructionGastrointestinal disorders | 0/38 | 0/11 | 4/73 | 1/69 |
| DehydrationMetabolism and nutrition disorders | 0/38 | 0/11 | 4/73 | 0/69 |
| Event | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 24/38 | 10/11 | 52/73 | 10/69 |
| DiarrhoeaGastrointestinal disorders | 27/38 | 8/11 | 46/73 | 15/69 |
| StomatitisGastrointestinal disorders | 15/38 | 8/11 | 46/73 | 6/69 |
| FatigueGeneral disorders | 26/38 | 8/11 | 43/73 | 31/69 |
| LeukopeniaBlood and lymphatic system disorders | 20/38 | 8/11 | 11/73 | 3/69 |
| AlopeciaSkin and subcutaneous tissue disorders | 26/38 | 5/11 | 28/73 | 22/69 |
| AnaemiaBlood and lymphatic system disorders | 22/38 | 7/11 | 33/73 | 20/69 |
| NauseaGastrointestinal disorders | 23/38 | 5/11 | 32/73 | 32/69 |
| ConstipationGastrointestinal disorders | 15/38 | 3/11 | 26/73 | 17/69 |
| Oedema peripheralGeneral disorders | 15/38 | 3/11 | 12/73 | 18/69 |
Safety population was defined as all participants who received at least 1 dose of any study drug.
| Age, Continuous(years) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 55.8 ± 10.29 | 58.6 ± 10.06 | 61.0 ± 11.60 | 60.8 ± 8.41 | 59.8 ± 10.32 |
| Sex: Female, Male(Participants) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Female | 38 | 11 | 73 | 69 | 191 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 1 | 4 | 9 |
| Not Hispanic or Latino | 34 | 10 | 64 | 62 | 170 |
| Not Reported | 0 | 1 | 7 | 3 | 11 |
| Missing | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| White | 34 | 11 | 66 | 55 | 166 |
| Black or African American | 3 | 0 | 2 | 6 | 11 |
| Asian | 1 | 0 | 1 | 2 | 4 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 2 | 2 |
| Other | 0 | 0 | 1 | 1 | 2 |
| Not Reported | 0 | 0 | 2 | 3 | 5 |
| Missing | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| United States | 38 | 11 | 48 | 45 | 142 |
| Poland | 0 | 0 | 10 | 8 | 18 |
| France | 0 | 0 | 15 | 16 | 31 |
| Height(cm) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 164.2 ± 6.41 | 164.5 ± 6.38 | 162.4 ± 7.02 | 161.9 ± 7.30 | 162.7 ± 6.99 |
| Weight(kg) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 75.86 ± 16.41 | 76.29 ± 7.29 | 70.42 ± 14.78 | 72.50 ± 18.71 | 72.59 ± 16.37 |
| Body Surface Area(m^2) | Alisertib (Phase 1 - Ovarian Cancer) | Alisertib (Phase 1 - Breast Cancer) | Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2) | Paclitaxel 80 mg/m^2 (Phase 2) | Total |
|---|---|---|---|---|---|
| Mean | 1.850 ± 0.21 | 1.865 ± 0.10 | 1.776 ± 0.20 | 1.794 ± 0.24 | 1.802 ± 0.21 |
Ran from Apr 2010 to primary completion in Aug 2014, 51 months.
Results were first posted in Jun 2018, 3 years 9 months after primary completion. A results delay was requested in Feb 2017.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 51 months is above that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Millennium Pharmaceuticals, Inc. →